Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Solid Tumors × cemiplimab × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 33 Melanoma 13 Neoplasm Metastasis 11 Squamous Cell Carcinoma of Head and Neck 10 Skin Neoplasms 10 Lung Neoplasms 9 Recurrence 7 Neoplasms 7 Ovarian Neoplasms 6 Colorectal Neoplasms 6 Carcinoma, Squamous Cell 6 Carcinoma, Renal Cell 6 Adenocarcinoma 6 Urinary Bladder Neoplasms 5 Carcinoma, Basal Cell 5 Triple Negative Breast Neoplasms 4 Prostatic Neoplasms 4 Head and Neck Neoplasms 4 Glioblastoma 4 Colonic Neoplasms 4 Carcinoma 4 Breast Neoplasms 4 Uterine Cervical Neoplasms 3 Pancreatic Neoplasms 3 Mycosis Fungoides 3 Fallopian Tube Neoplasms 3 Cutaneous Squamous Cell Carcinoma 3 Carcinoma, Merkel Cell 3 Uveal Melanoma 2 Stomach Neoplasms 2

Interventions

Injections 16 Carboplatin 8 pembrolizumab 7 Bevacizumab 7 Leucovorin 6 Fluorouracil 6 Docetaxel 5 Pemetrexed 4 Paclitaxel 4 Oxaliplatin 4 trifluridine tipiracil drug combination 3 atezolizumab 3 Capecitabine 3 tislelizumab 2 spartalizumab 2 sotorasib 2 palbociclib 2 olaparib 2 fludarabine 2 Panitumumab 2 Irinotecan 2 HMPL-013 2 Fulvestrant 2 Etoposide 2 Drug Therapy 2 Cyclophosphamide 2 Cisplatin 2 Cetuximab 2 130-nm albumin-bound paclitaxel 2 zimberelimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04626635 2026-02-02

COMBINE-EGFR-1

Regeneron Pharmaceuticals

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡